Arcellx, listed on the NASDAQ:ACLX, is a biotechnology company focused on developing innovative cancer therapies. Recently, Cory Kasimov from Evercore ISI set a price target of $115 for ACLX. At the time, the stock was trading at $113.81, indicating a slight 1.04% difference from the target. This reflects investor optimism surrounding the company's potential growth.
Gilead Sciences has announced its intention to acquire Arcellx for up to $7.8 billion, marking its largest deal since 2020. This acquisition aims to enhance Gilead's cancer treatment portfolio, as highlighted by the Wall Street Journal. The news has significantly impacted ACLX's stock, with shares soaring 77.8% to $113.99 in premarket trading.
The acquisition has led to a substantial increase in ACLX's stock price, which is currently at $113.80, reflecting a 77.50% rise with a change of $49.69. The stock has fluctuated between $113.72 and $114.26 today, marking its highest price in the past year. The lowest price for the year was $47.86.
ACLX's market capitalization now stands at approximately $6.58 billion, with a trading volume of 27.91 million shares. This acquisition underscores Gilead's strategic move to expand its portfolio in the cancer therapy sector, further boosting investor confidence in ACLX's future prospects.
